This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Intervention Trial in Early Age-related Macular Degeneration (I-TEAM)

This study has been completed.
Sprim Advanced Life Sciences
Information provided by (Responsible Party):
Newtricious R&D BV Identifier:
First received: September 25, 2012
Last updated: September 20, 2016
Last verified: September 2016
The purpose of the I-TEAM project is to assess whether there is a change in visual function and status of the retina after a year of intervention in subjects with early signs of Age-related Macular Degeneration.

Condition Intervention
Age-related Macular Degeneration (AMD) Dietary Supplement: Lutein-enriched-egg beverage (NWT-02) Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Intervention Study to Assess the Effect of Daily Consumption of a Lutein-enriched-egg Beverage on Maintenance of Visual Function in Subjects With Early Signs of Age-related Macular Degeneration

Resource links provided by NLM:

Further study details as provided by Newtricious R&D BV:

Primary Outcome Measures:
  • Visual function [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • Carotenoid levels [ Time Frame: 12 months ]
    Levels of lutein and Zeaxanthin

Enrollment: 120
Study Start Date: October 2012
Study Completion Date: April 2016
Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Lutein-enriched-egg beverage
Powder in sachets is provided and dissolved to prepare Lutein-enriched-egg beverage
Dietary Supplement: Lutein-enriched-egg beverage (NWT-02)
Lutein, zeaxanthin and DHA-enriched-egg yolk combined with buttermilk beverage
Placebo Comparator: Placebo
Powder in sachet to prepare beverage
Dietary Supplement: Placebo
color-, taste- and energy-matched powder without enriched egg-yolk


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Early AMD (AREDS category 2)

    • many small drusen, or
    • a few intermediate-sized (63-124 micrometres in diameter) drusen, or
    • macular pigmentary changes


  • Intermediate AMD (AREDS category 3)

    • extensive intermediate sized (63-124 micrometres in diameter) drusen, or
    • at least one large (>125 micrometers in diameter) drusen or
    • geographic atrophy not involving the foveal centre
  • men and women age ≥50 years
  • BMI 18-35 kg/m2
  • Vision ≥ 20/40 for Snellen visual acuity
  • lutein intake of < 2 mg/day (including supplements)
  • DHA intake of < 150 mg/day (including supplements)
  • must be able to give written informed consent
  • have normal hematologic parameters
  • normal values of plasma albumin
  • normal values for liver and kidney function
  • no use of carotenoid, fish oil, or n3 fatty acid supplements (within 1 month of study start)

Exclusion Criteria:

  • ocular media opacity (severe cataract)
  • history of active small bowel disease or resection
  • atrophic gastritis
  • history of hyperlipidemia or screening values as follows (LDL > 5.33mmol/L or 205mg/dL; triglycerides > 4.52mmol/L or >400 mg/dL)
  • hypertension (>150/90 mm Hg)
  • diabetes mellitus (if also accompanied by signs of diabetic retinopathy)
  • alcohol intake of >2 drinks/day or 14 drinks/week
  • pancreatic disease
  • dementia or Alzheimer's disease
  • anemia, and bleeding disorders
  • known allergy to egg or egg products
  • known allergy to milk or milk products
  • known allergy to cocoa or chocolate products
  • known allergy to fish or fish oils
  • lactose intolerance
  • pregnancy or lactation
  • diseases that interfere with fat absorption, e.g. colitis, celiac disease, Crohn's disease, cystic fibrosis (as determined by screening interview)
  • medication or supplements that contain a significant level of carotenoids, including an amount of lutein of more than 0.25 mg per day within 1 month of the study start
  • medications that interfere with fat absorption, e.g. bile sequestrants (as determined by screening interview)
  • use of antipsychotic, anti manic, or dementia medications
  • smoking or use of nicotine patches or gum (within the past 6 months)
  • subjects having extremely high dietary intakes of carotenoids
  • stroke, head injury with loss of consciousness or seizures
  • for US and UK center: Non English speaking
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01694680

United States, Massachusetts
TUFTS University
Boston, Massachusetts, United States
Universitäts Augenklinik - Bonn
Bonn, Germany
Radboud University Hospital
Nijmegen, Netherlands, 6525EX
United Kingdom
Manchester Royal Eye Hospital - Manchester
Manchester, United Kingdom
Sponsors and Collaborators
Newtricious R&D BV
Sprim Advanced Life Sciences
Principal Investigator: E J Johnson, PhD Jean Mayer USDA Human Nutrition Research Center on Aging (HNRCA), Boston
  More Information

Responsible Party: Newtricious R&D BV Identifier: NCT01694680     History of Changes
Other Study ID Numbers: NWT-02/Human 4
Study First Received: September 25, 2012
Last Updated: September 20, 2016

Keywords provided by Newtricious R&D BV:
Visual function
Early signs of AMD
AREDS-category 2

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases processed this record on August 23, 2017